Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

REVENIO’S NEW FUNDUS IMAGING DEVICE AUTHORIZED FOR SALE IN THE UNITED STATES AND EUROPE

Revenio Group Corporation Press release December 9, 2019, at 9:00 am EETDRSplus, the newest addition to CenterVue’s family of fundus imaging devices, has been approved by the Food and Drug Administration in the USA and CE certified in Europe. This means that the sales and marketing of the new product will start in 2019 in Europe and early 2020 in the United States. Revenio acquired CenterVue in April 2019. First launched in 2011, CenterVue’s widely successful DRS device will gradually be replaced by the DRSplus model which is especially well suited for the evaluation of diabetic

Svenska Aerogel Holding (publ) signs Letter of Intent with Worlée Chemie, Germany

A collaboration for introduction and market development of Quartzene has been formalized in a Letter of Intent between Svenska Aerogel Holding AB (Publ) and Worlée Chemie, Germany. Successful collaborations for Svenska Aerogel and Worlée Chemie. Reunion in November at China Coat in Shanghai. Sara Wengström, Account Manager Svenska Aerogel Torsten Adebahr, Head of Traded Products Division Worlée Chemie GmbH Roland Ek, Product Manager Svenska Aerogel The aim is to develop business in specified applications and allowing Svenska Aerogel access to Worlee's growing network

Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis

STOCKHOLM, December 9[th], 2019, Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint as well as key secondary endpoints in the North American Phase 3 study including 365 patients with mild to moderate toenail onychomycosis (nail fungus). At week 52, significantly more patients reached complete cure for MOB-015 than for vehicle (p=0.019), following 48 weeks of daily treatment.The purpose of this randomized, multicenter, controlled clinical Phase 3 study was to evaluate the efficacy and safety of MOB-015 in patients with mild to moderate distal

SAS to Open Direct Route to Haneda

Scandinavian Airlines System (SAS) is pleased to announce a direct route to Tokyo Haneda International Airport from Copenhagen Kastrup. The route gives travelers better access to downtown Tokyo and with All Nippon Airways (ANA), a fellow Star Alliance member, the route will increase connectivity to 30 domestic destinations in Japan.The direct Copenhagen-Haneda route will be served by SAS’ new Airbus A350 aircraft. As the most environmental-friendly airplane on the market, the A350 will reduce emissions by 30 percent compared to earlier generations of similar long-haul aircraft. “Japan is

IRRAflow[®] Wins CONNECT’s “2019 Most Innovative New Product” Award

Breakthrough medical device that transforms treatment of intracranial bleeding recognized as most innovative new medical device from southern California Stockholm, Sweden, December 9, 2019 – IRRAS AB (NASDAQ Stockholm: IRRAS), a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced today that IRRAflow has been selected as the 2019 winner of CONNECT’s Most Innovative New Product award in the medical device category. CONNECT, a premier nonprofit helping entrepreneurs with innovative startups in the technology and life sciences

FarmPharma signs agreement with Karolinska Institutet

Today FarmPharma AB, the subsidiary of Double Bond Pharmaceutical AB, signed a collaboration agreement with Karolinska Institutet (Department of Medicine, Solna) to conduct a project of producing start material for FarmPharma products. The work is estimated to start immediately. The goal of the project is the large-scale testing of the production of InterferOX parts and the company’s other products in order to facilitate the transition to GMP production. “We are happy to be able to collaborate with world’s class researchers to fuel the development of PharmPharma’s products”, comments

Today, trading in warrants of series 2-2019 will commence

On December 9, 2019, trading will commence in Enersize Oyj's ("Enersize") warrants of series 2-2019 (TO2). The warrants are traded with ISIN code FI4000399761 and under the ticker "ENERS TO 2". The last trading day is August 27, 2020.In total, there are 29 412 972 outstanding warrants of series 2-2019. The warrants of series 2-2019 (TO2) have a strike period from August 31, 2020 through September 11, 2020. The strike price is equivalent to 70 percent of the volume-weighted average price during the period from August 13, 2020 through August 27, 2020, however, never higher than SEK 1.30 (EUR

Skanska sells care home in Gothenburg, Sweden, for about SEK 290 M

Skanska has sold a care home in Gothenburg, Sweden, for about SEK 290 M. The buyer is Altura. The transaction will be recorded in the Commercial Property Development stream in the fourth quarter 2019. The transfer will take place in the summer of 2021. A lease agreement has previously been signed with Vardaga.The four-storey Villa Kviberg will consist of 77 apartments and comprise a total of 5,000 square meters. It will be located in an area where Skanska has developed the residential project Kvibergs Ängar. The care home, which is developed and built by Skanska Sweden, has high

Share buy-backs in Telia Company during week 49 2019

During the period December 2, 2019, until December 6, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2,832,173 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back program that Telia Company announced on April 16, 2019. The share buy-back program, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation"). During the period

Kungsleden makes strategic acquisition in existing Stockholm cluster

Kungsleden continues to expand its office portfolio and strengthen its presence in the existing Stockholm City West cluster through the acquisition of the Gladan 4 property in Kungsholmen for SEK 428 million.The property will be acquired from Areim and includes a 7,600 sq.m office building. The annual rental value is just over SEK 25 million and the largest tenants are LRF Konsult, Förlagssystem, Region Stockholm/Stockholms Läns Landsting and GEP Communication Group. The transaction will be finalised on December 12, 2019. Kungsleden already owns six properties in Stockholm City West and

COSEL expands UL/EN62368-1 certified low profile open frame power supplies for demanding applications

•    Low profile open frame (27mm, 1.07”)•    Safety approvals UL62368-1, c-UL (equivalent to CAN/CSA-22.2 No.62368-1), EN62368-1•    Harmonic attenuator IEC61000-3-2 compliant (Class A)•    Wide temperature range -10 to +70 degrees C•    High reliability – 5-year warranty  Cosel Co, Ltd (6905: Tokyo) today announced the addition of four new series of open frame, low profile, compact power supplies covering the range of 30W to 100W and UL/EN62368-1 certified. The LHA30F, LHA50F, LHA75F and LHA100F complement Cosel’s existing, leading LHA150F and LHA300F models, now offering an

A sustainable new material for carbon dioxide capture

In a joint research study from Sweden, scientists from Chalmers University of Technology and Stockholm University have developed a new material for capturing carbon dioxide. The new material offers many benefits – it is sustainable, has a high capture rate, and has low operating costs. The research has been published in the journal ACS Applied Materials & Interfaces. Carbon Capture and Storage (CCS) is a technology that attracts a lot of attention and debate. Large investments and initiatives are underway from politicians and industry alike, to capture carbon dioxide emissions and tackle

NPRO: Agreement on acquisition of property in Oslo inner city No

Norwegian Property has entered into an agreement to purchase the property Lille Grensen 7. NPRO will purchase all shares in Grensen Investment AS, which is the owner of 100% of the shares in Lille Grensen 7 AS. The agreed gross value for the property is MNOK 710. Takeover is estimated to take place on 17 December 2019. The property is located centrally in Oslo Inner City, next to Karl Johan Street, and with a view to the Norwegian Parliament building, Stortinget. It is situated next to the subway station. CEO, Bent Oustad, comments: “We are very satisfied with the acquisition of

BerGenBio presents preliminary clinical data from Phase II combination trial of bemcentinib and LDAC in elderly AML patients at ASH 2019

· Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC)  in elderly AML patients unfit for intensive therapy is well tolerated and shows promising efficacy · Long duration of response (>9.9 mo, still maturing) with 50% CR/CRi in 6 evaluable newly diagnosed patients receiving the bemcentinib-LDAC combination. · Clinical benefit demonstrated in >2L relapsed and refractory AML patients with 1 CR/CRi and 3 SD out of 6 evaluable patients · Pretreatment sAXL holds as predictive of response Bergen, Norway, December 9, 2019 – BerGenBio ASA (OSE:BGBIO), a

New XPG CPU Cooler Incorporates Asetek Liquid Cooling Technology for Advanced Overclocking Capability

XPG All-In-One from ADATA Combines Extreme Performance with Addressable RGB AestheticsAalborg, Denmark – December 9, 2019 –– Asetek, the creator of the all-in-one liquid cooler and the global leader in liquid cooling solutions for gaming PCs and DIY enthusiasts, announced that ADATA has introduced its first CPU liquid cooler, leveraging the superior thermal and acoustic performance and reliability associated with Asetek technology. The XTREME PERFORMANCE GEAR (XPG) LEVANTE 240 Addressable RGB cooler provides advanced CPU overclocking capability and virtually silent operation to gamers,

Share buy-backs in Green Landscaping Group during week 49 2019

During the period December 2, 2019, until December 6, 2019, Green Landscaping Group AB (publ) has repurchased in total 11 600 own shares (ISIN-code: SE0010985028). The share buy-backs form part of the SEK 5 million share buy-back program that Green Landscaping announced on October 24, 2019. The share buy-back program, which runs between November 6, 2019, and May 14, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period December 2, 2019, and

QuickCool AB (publ): The Board of QuickCool AB (publ) needs additional time to complete the negotiations on the company's long-term financing

On November 24, 2019, the Board of Directors of QuickCool AB (publ) resolved to withdraw proposals for resolutions at the Extraordinary General Meeting in light of the ongoing negotiations being conducted by the Board on the Company's future financing and operations. The Board has continued to evaluate available financing options and negotiate various arrangements.The Board needs additional time to analyze and decide on the structure that best takes into account the interests of the shareholders. The Board's previous assessment that the negotiations could be completed within a two-week

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive efficacy in combination with daratumumab or bortezomib in patients with relapsed/refractory multiple myeloma (RRMM). Preclinical data supporting clinical development of melflufen in AL amyloidosis will also be presented for the first time.Overall Conclusions – ANCHOR Poster Presentation · Patients in the ANCHOR

Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019

STOCKHOLM — December 7, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with late-stage relapsed/refractory multiple myeloma (RRMM). The safety profile remained consistent with prior reports from the HORIZON study. These data reinforce Oncopeptides’ view that melflufen can play a role in the treatment of patients with RRMM and the Company plans to submit a New Drug Application

Ericsson reaches resolution on U.S. FCPA investigations

· Ericsson has entered into a three-year Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ) to resolve criminal charges related to violations of the FCPA.  This relates to accounting violations of the FCPA in five countries including in Djibouti where there is also a charge of bribery. In the agreement, the DOJ agrees to defer the prosecution of those charges and to have them dismissed at the end of the term in exchange for Ericsson complying with the conditions of the DPA. Conditions include a payment by Ericsson of a fine of USD 520,650,432. As part of the

Elekta completes its investment in ViewRay

STOCKHOLM, December 6, 2019 – Elekta AB (EKTA-B.ST) announced today that that it has completed its investment in ViewRay, Inc. (Nasdaq:VRAY), which was announced on December 2, 2019.  Elekta has invested USD 36 M for 11,501,597 shares of common stock of ViewRay, corresponding to approximately 7.6 percent of the outstanding common stock in ViewRay on a fully diluted basis in the underwritten public offering. The price was set at USD 3.13 per share, pursuant to the Elekta’s commitment agreement with ViewRay. # # # For further information, please contact:Oskar Bosson, Global EVP

The prospectus will be published week 50

The prospectus being produced on the basis of the rights issue, announced on November 18, 2019, will be published no earlier than Monday week 50. About Brighter AB (publ) Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on

Intrum extends and increases its Revolving Credit Facility

Intrum has extended the maturity of the Revolving Credit Facility (RCF) with five plus one year and increased the amount from EUR 1.375bn to EUR 1.8bn. The new facility will cater for Intrum’s long-term growth ambition and assures an appropriate liquidity buffer and Intrum’s underwriting capabilities going forward. The new facility will start in January 2020.  - Intrum has increased the number of participating banks with eight new international lenders and also secured improved terms to further match our capital structure ambition. We welcome the additional lending banks to Intrum and we

Investor Report

To view this report in PDF, please click on the following link: http://www.rns-pdf.londonstockexchange.com/rns/1170W_1-2019-12-6.pdf       RBC Covered Bond Programme Monthly Investor Report Calculation Date:                                      10/31/2019     This report contains information regarding assets pledged as security (theCover Pool) in respect of the obligations under the Covered Bonds issued underRBC's Global Covered Bond Programme as of the indicated Calculation Date.  Thecomposition of the Cover Pool will change as Loans are added and removed from

There are no items matching the current filter
There are no more items matching the current filter
Back to top